Paclitaxel treatment frequently cause peripheral neuropathy, an adverse event that can limit treatment course and lead to permanent symptoms drastically decreasing quality of life. Our group has contributed to the identification and validation of common polymorphisms in EPHA genes associated with paclitaxel neuropathy, but a large part of the inter-individual variation in neuropathy remains unexplained. We hypothesized that low-frequency variants with strong effects may contribute to the neuropathy variability in patients. By performing targeted exon sequencing of candidate genes we found for the first time that patients carrying low-frequency non-synonymous coding variants in EPHA5/6/8 contribute to paclitaxelinduced neuropathy susceptibility. Furthermore, these genes might also be relevant neuropathy markers for other neurotoxic drugs due to the involvement of Eph receptors in neuronal functions.
Translational Relevance
Paclitaxel treatment frequently cause peripheral neuropathy, an adverse event that can limit treatment course and lead to permanent symptoms drastically decreasing quality of life. Our group has contributed to the identification and validation of common polymorphisms in EPHA genes associated with paclitaxel neuropathy, but a large part of the inter-individual variation in neuropathy remains unexplained. We hypothesized that low-frequency variants with strong effects may contribute to the neuropathy variability in patients. By performing targeted exon sequencing of candidate genes we found for the first time that patients carrying low-frequency non-synonymous coding variants in EPHA5/6/8 contribute to paclitaxelinduced neuropathy susceptibility. Furthermore, these genes might also be relevant neuropathy markers for other neurotoxic drugs due to the involvement of Eph receptors in neuronal functions.
INTRODUCTION
The anticancer agent paclitaxel is a microtubule inhibitor widely used in the treatment of many solid tumors (1) . Peripheral neuropathy is its dose-limiting toxicity (2) , and severe neuropathy cases with an important reduction in the quality of life of the patients are not rare (3, 4) . The lack of effective treatments for the neuropathy creates an urgent need to identify markers that can help to personalize treatment and avoid severe neuropathy events. The patient genetic background has been proposed to play a relevant role in the susceptibility for suffering neuropathy (5) . In this regard, paclitaxel pharmacokinetic (6, 7) and pharmacodynamic (8, 9 ) pathways have been included in studies of candidate genes and, more recently genome-wide association studies (GWAS) have been performed (10, 11) .
Candidate gene studies, by us and other groups, have demonstrated that common variants in paclitaxel metabolizing enzymes and paclitaxel target (i.e. CYP2C8*3 (12) (13) (14) , CYP3A4*22 (7) , TUBB2A rs909964 and rs909965 (8, 9) ) influence neuropathy risk, while genome wide genotyping has uncovered novel genes (10, 11) . A GWAS by our group (11) suggested that the EPHA gene family, which plays a key role in the development of nervous system and in nerve injury repair (15) (16) (17) , was a key player for paclitaxel neuropathy susceptibility. Meta-analysis of GWAS top hits showed that EPHA5 rs7349683 reached genome-wide significance (11) , and follow-up studies further supported that this variant (18) , EPHA6 rs301927 (9, 18) and EPHA8 rs209709 (18) moderately increased paclitaxel-induced neuropathy risk. However, large part of the variation in paclitaxel-induced neuropathy remains unexplained.
Low-frequency variants with strong effects may contribute to the neuropathy variability observed in patients. To investigate this hypothesis sequencing technologies are required and, so far, only two exploratory studies following different strategies have been performed. In one we applied whole exome sequencing to few extreme neuropathy patients, and identified defective CYP3A4 variants associated with the neuropathy (19) . The second study sequenced genes causative of familial polyneuropathies (Charcot-Marie-Tooth, CMT), and suggested ARHGEF10 and PRX as chemotherapy-induced neuropathy markers (20) .
These initial studies are promising, however, the statistical power for a whole exome sequencing study is low and in the CMT analysis key genes were excluded.
Here, we performed targeted exome sequencing of genes with common variants associated with paclitaxel-induced neuropathy (EPHA4, EPHA5, EPHA6 and EPHA8) plus genes involved in paclitaxel pharmacokinetics and in CMT. In total we sequenced 39 genes in 228 selected patients with high or no/low paclitaxel-induced neuropathy. The strongest association corresponded to EPHA6, and the relevance of low frequency EPHA5/6/8 nonsynonymous coding variants was validated in an independent cohort of 202 paclitaxel-treated patients. These results reveal EPHA genes as key players in chemotherapy-induced neuropathy and stress the importance of gene sequencing for identifying genetic risk factors of neuropathy.
PATIENTS AND METHODS

Patients
The discovery series was derived from a set of 449 breast or ovarian cancer patients treated with paclitaxel (97% in first line), with DNA available, no previous neurotoxic drug treatments and with clinical data and neuropathy assessment; some have already been reported (18, 19, 21) . In these patients the neuropathy was homogenously graded (19) , and 228 were selected for whole or targeted exon deep-sequencing, based on extreme-neuropathy phenotype. Among them, 131 were high-neuropathy patients that fulfilled the following criteria: grade 3 or 2 neuropathy (NCI-CTC v4) during paclitaxel treatment, no neuropathy risk factors (diabetes, alcoholism, AIDS or previous neuropathies), and treatment modifications due to neuropathy (dose reduction or treatment suspension) or neuropathy that lasted >6 months after paclitaxel treatment finished. The remaining 97 patients were no/lowneuropathy patients with no neuropathy signs or grade 1 neuropathy after receiving paclitaxel (Table 1 ).
The validation of results was performed in an independent series of 202 paclitaxeltreated patients with neuropathy data recorded cycle by cycle. Most patients had breast or ovarian tumors, 109 were Spanish (54%) and 93 Swedish (46%). 129 samples corresponded to a previous GWAS study (11), 37 to Spanish patients already described (18) and 36 samples were new cases collected in Spain. From all patients cumulative paclitaxel dose up to grade 2 (NCI_CTC v2/4) neuropathy was available (Table 1 ).
All individuals participating in the study were over 18 years of age, had been diagnosed of cancer with histological confirmation, a life expectancy of ≥12 weeks and ECOG performance status ≤2, adequate bone marrow and renal and hepatic function. The recruitment of patients and collection of samples was approved by local internal ethical review committees and all patients gave written informed consent to participate in the study.
Next generation sequencing (NGS)
From the 228 patients used in the discovery series, 196 samples were processed using the TruSeq Custom Amplicon Kit (Illumina) covering the coding plus 25 bp intronic flanking region of 39 genes that included: EPHA4, EPHA5, EPHA6 and EPHA8 (10, 11) plus additional genes involved in paclitaxel metabolism and transport (ABCB1, CYP2C8, CYP3A4, SLCO1B1, SLCO1B3) and a selection of 30 genes associated with CMT hereditary peripheral neuropathies (Fig. 1) . Very conserved CMT genes with no/very few variants reported were not selected for sequencing (e.g. ATL1, EGR2, GDAP1, GJB1, LMNA, PRPS1, RAB7A, YARS). In brief, 150 ng of DNA extracted from peripheral blood (FlexiGene DNA Kit, Qiagen) was used to construct libraries and sequenced in a MiSeq sequencer (Illumina, Spain) with a paired-end mode using MiSeq Reagent Kit V3 (Illumina, Spain) and 600 cycles. In addition, whole exome sequencing was performed on the remaining 32 patients (16 with high neuropathy (8 have been reported (19) ) and 16 patients with no neuropathy), as previously described (19) . For the validation of the results, a TruSeq Custom Amplicon Kit (Illumina) including the coding and intronic flanking region of EPHA5, EPHA6 and EPHA8 was used.
Variant identification
Targeted NGS data was demultiplexed with MiSeq Reporter (Illumina). Alignment was performed using Smith-Waterman algorithm (22) using GRCh37/hg19 assembly as reference and Genome Analysis Toolkit v2 (GATK, (23)) was used for raw variant calling.
For the 32 samples with whole exome sequencing data, alignment and variant calling were performed by RUbioSeq software v3.7 (24) . In this software the alignment was performed using Burrows-Wheeler alignment (25) , unmapped reads are realigned using BFAST (26) and for variant calling, GATK v2 was used (23 Variants included in the analysis were: i) those previously described in public databases (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/; Exome Aggregation Consortium (ExAC), http://exac.broadinstitute.org), and ii) variants not previously described with: high variant call quality (Q>30), read depth >10X and alternative variant frequency higher than 0.3 in at least one individual. Sequencing artefacts, defined as nucleotide changes detected in >20 samples in the sequencing panel but never described in ExAC, were omitted from the analysis. We defined loss of function (LOF) variants as those introducing stop codons (nonsense), variants disrupting canonical splice sites and indels disrupting the reading frame.
Template and configuration files for alignment and scripts are available at https://github.com/htejero/PaclitaxelNeuropathy.
Validation of variants was performed by Sanger sequencing with an ABI PRISM 3700 DNA Analyzer capillary sequencer (Applied Biosystems) on 3% of the LOF and missense variants included in the analysis.
Data analysis
Variants were classified as "common variants" if they had a minor allele frequency (MAF) ≥0.5% in the more than 30.000 sequenced non-Finnish Europeans from ExAC.
Variants were classified as "low frequency variants" if they had a MAF <0.5% in the non- genes with ≥ four rare variants were included in the analysis.
The study followed a 2-step design in which the best candidates from the discovery phase were selected for validation in an independent cohort of paclitaxel-treated patients (Table 1 shows discovery and validation series). No correction for multiple testing was performed. For samples with cycle by cycle neuropathy data, the association between EPHA variants and paclitaxel neuropathy risk was tested using Kaplan-Meier analysis, modelling the cumulative dose of paclitaxel up to the development of neurotoxicity grade ≥2. Patients with no or low neuropathy (grade 0/1) were censored at total administered cumulative dose. We also evaluated the association using univariate and multivariable Cox regression analysis (14) .
Country of origin and treatment schedule (1h versus 3h infusion) were included as covariates in the multivariate analyses. SPSS software package v.19 was used for these analyses. P values less than 0.05 were considered statistically significant.
RESULTS
Study population and NGS
NGS was performed on selected cases: 131 patients with high neuropathy (grades 2/3 that lasted a mean of 55 months) despite low accumulated paclitaxel dose (median= 1295 mg) and 97 patients with no/low neuropathy (grades 0/1) despite high accumulated paclitaxel dose (median= 1485 mg) ( Table 1 ). In addition, 33% of patients in the high neuropathy group had paclitaxel dose reductions or treatment suspensions caused by the neuropathy.
Sequencing of 39 candidate genes in the 228 patients identified 277 coding nonsynonymous or canonical splice site variants (266 missense, 3 in-frame deletions, 8 LOF;
Suppl. Table 1 ). From these, 86 were common variants and 191 low-frequency variants.
At least one common variant was identified in each sequenced gene, except for
CYP3A4, EPHA4, HSPB1, HSPB8, NEFL, NDRG1 and SPTLC2.
When the presence of these common variants was compared among the neuropathy groups, association with paclitaxel neuropathy was found for only 2 SNPs located in CYP2C8 and PRX (P<0.05; Suppl. Table 2 ).
The 191 low frequency variants were distributed among all sequenced genes, except for NEFL and NGF. Of these 191 variants, 8 were loss of function (3 altered canonical splice sites, 2 were nonsense variants and 3 were indels causing frameshifts leading to premature stop codons; Table 2 ).
Gene-based analysis of paclitaxel-induced neuropathy in the discovery series
Analysis of the low frequency variants identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy ( (15) (16) (17) and also belonged to the high-neuropathy risk group of genes (Table 3 ). In EPHA5, 5 carriers had high neuropathy versus 1 with low neuropathy; and in EPHA8, 9
carriers were in the high neuropathy and 6 in the no/low neuropathy group ( Fig. 2 ; Suppl. Fig. 3A ).
Low frequency variants in EPHA6, EPHA5 and EPHA8 confirmed as neuropathy risk factor in the validation series
Sequencing EPHA5/6/8 in an independent cohort of 202 patients treated with paclitaxel and detailed cycle by cycle neuropathy data (Table 1) , revealed 15 carriers of low frequency missense variants in these genes (one corresponded to EPHA6, one to EPHA5 and 13 to EPHA8). These variants were combined and an accumulated paclitaxel dose analysis revealed that low frequency EPHA5/6/8 variants conferred increased risk of neuropathy (HR=2.07, 95%CI=1.14-3.77, P=0.017; Fig. 3B ).
Combining discovery and validation series, resulted in a HR of 2.50 (95%CI=1.46-4.31) with a P value of 9.1x10 -4 (Fig. 3C) .
DISCUSSION
Paclitaxel induced-neuropathy is a clinically relevant toxicity affecting large number of cancer patients. Genetic variation has been shown to influence susceptibility to paclitaxelinduced neuropathy, however, a large part of the variation remains unexplained. Lowfrequency variants with strong effects may explain part of the variability. To investigate this hypothesis, we performed massive sequencing of candidate genes in patients selected based on extreme-neuropathy phenotype. Gene-based analysis identified, for the first time, low frequency genetic variants in EPHA5/6/8 as risk factors of chemotherapy induced neuropathy.
These results may provide a basis for personalizing paclitaxel treatment and decreasing the incidence of severe chemotherapy-induced neuropathies.
GWAS studies have identified common variants in EPHA genes with moderate effects on paclitaxel-induced neuropathy (EPHA5-rs7349683, EPHA6-rs301927, EPHA8-rs209709
and EPHA4-rs17348202) (10, 11) and subsequent studies further supported the association of EPHA5, EPHA6 and EPHA8 polymorphisms (9, 18). Non-synonymous coding variants, potentially affecting protein function, are expected to have stronger effects on neuropathy than common regulatory variants (28) . Following this idea, we performed a NGS study in EPHA genes, together with paclitaxel pharmacokinetics and hereditary peripheral neuropathy related genes. Gene-based analysis of our data revealed that low frequency missense variants in EPHA6 increased paclitaxel-induced neuropathy risk. All these variants were located in the ephrin receptor ligand binding domain, suggesting an alteration of the protein function and further supporting the association. EPHA5 and EPHA8 followed a similar trend (Fig. 2) . In total, 15% (19 of 131) of patients in the high neuropathy group carried low frequency nonsynonymous coding variants in EPHA5/6/8 genes. In the 202 patients of the validation series, 13 EPHA8 variant carriers were identified but only one EPHA6 and one EPHA5 carriers were detected, suggesting that EPHA6 and EPHA5 variants (present in 5 out of the 131 patients with high-neuropathy of the discovery) are less frequent in an unselected patient population, including many moderate-neuropathy patients (not represented in the discovery set). Thus, EPHA6 and EPHA5 variant carriers were scarce in the validation series, and the calculated EPHA-effect mainly derived from EPHA8. Despite this, the accumulated dose analysis is a sensitive approach (18, 21) and was able to detect a statistically significant association.
Altogether, these data suggest a relevant role for EPHA5/6/8 genes in paclitaxel-induced neuropathy and indicates a high impact of low frequency variants missed in GWAS.
Eph receptors are tyrosine kinases involved in neural development (15) In ExAC database 0.1% of the European non-Finish population are carriers of LOF variants in either EPHA5, EPHA6 or EPHA8, and on >100,000 Islandic individuals, two complete human knockouts for EPHA5 and one for EPHA6 were identified (44) . So far, no phenotype has been assigned to these individuals who are apparently healthy subjects.
However, based on the literature and on our results, a high susceptibility to drug-induced neuropathy would be expected.
Concerning other genes potentially associated with the neuropathy, in line with
Beutler et al (20) we postulated that variants moderately affecting the function of CMT genes,
while not being pathogenic, may increase the susceptibility to drug-induced neuropathy. We did not find low frequency variants in PRX and common variants in ARHGEF10 associated with paclitaxel-induced neuropathy, although the 2 nd and 3 rd top protective genes were these two, similarly to Beutler et al. For the ARHGEF10 common variant rs9657362 we also found a trend towards protection (20, 45) . We also observed a trend towards increased neuropathy risk for other CMT genes (SEPT9 and SH3TC2). Variability in results among studies may be related to differences in neuropathy definitions/ assessments, in tumor types and patient treatments, or in the distribution of low-frequency variants, which have shown to be population-specific. Thus, results need to be further explored and validated in large independent series.
With regards to the LOF variants detected in this study, three occurred in CMT genes (ARHGEF10, IKBKAP and DHTKD1). The patients with variants in ARHGEF10 and IKBKAP belonged to the no/low neuropathy group, in agreement with the fact that activating rather than LOF mutations in ARHGEF10 cause CMT (46) and that no phenotype is observed for IKBKAP heterozygous individuals (47) . The variant in DHTKD1 was present in two patients with different neuropathy, but recent data question the role of this gene in CMT disease (48, 49) . Among the remaining LOF variants, two affected EPHA genes (EPHA5 and EPHA8) and corresponded to high-neuropathy patients. One LOF variant occurred in the paclitaxel uptake transporter SLCO1B1, in a high neuropathy patient. Two occurred in CYP3A4, a gene in which we have demonstrated that defective variants increased neuropathy risk (19) . Two patients were carriers of the CYP3A4*20 frameshift allele and belonged to the high-neuropathy group, but one patient with a splicing defect affecting the last exon belonged to the no/low neuropathy group. The effect of this latter variant on the splicing of the gene and how it affects function remains to be studied.
Although the main goal of this study was to identify neuropathy associated lowfrequency coding variants, we also found two common polymorphisms associated with the neuropathy: CYP2C8 rs1058930 (CYP2C8*4), for which previous studies have found contradictory results (9, 14) , and PRX rs268674, which was associated with neuropathy risk here for the first time. Further studies should evaluate the relevance of these results.
Limitations of this study include gene selection, since relevant genes not yet connected with neuropathy susceptibility may have been excluded. There are also differences in the selection of patients in the discovery and validation series. In the discovery series, patients were mainly treated with paclitaxel as single agent whereas in the validation cohort, the majority of the patients were treated with paclitaxel in combination with carboplatin. No major differences in neuropathy development between paclitaxel/carboplatin therapy versus paclitaxel as single agent exist (50, 51) . In addition, we adjusted the analysis using treatment schedule as covariate. Nevertheless, using a more homogenous series may have resulted in stronger association results. Detection of low/ moderate effects on neuropathy may require even larger samples sets, although the number of patients in this study is substantial and the neuropathy assessment was homogenously performed to reduce subjectivity (11, 19) . On the whole, additional studies validating the results in extensive and well characterized series of patients, the development of a model integrating all different risk markers identified, and providing with a standardized methodology to perform the genetic testing would be required to implement these risk factors into the clinics. 
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